Axsome Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
09 mai 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing...
Axsome Therapeutics To Report First Quarter 2019 Financial Results On May 9, 2019
29 avr. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Thursday, May 9, 2019 at 8:00 AM Eastern Time NEW YORK, April 29, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
14 mars 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing...
Axsome Therapeutics Secures $24 Million Growth Capital Loan Facility Led by Silicon Valley Bank
06 mars 2019 07h00 HE
|
Axsome Therapeutics, Inc.
$46 million total raised in recent financings extends cash runway into at least 4Q 2021 Current financial position fully funds all five ongoing clinical trials NEW YORK, March 06, 2019 (GLOBE...
Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy
30 janv. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Topline results anticipated in 2Q 2019 NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies...
Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility
07 janv. 2019 18h35 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Provides Year End 2018 Clinical Update
27 déc. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
FDA clearance of IND received for Phase 2 trial of AXS-12 in narcolepsy Phase 2 results of AXS-05 in major depressive disorder on track for early January 2019 Phase 3 results of AXS-05 in treatment...
Axsome Therapeutics to Present at Biotech Showcase 2019
18 déc. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Expands Loan Agreement with Silicon Valley Bank Providing Additional Growth Capital Related to AXS-12 Product Candidate
27 nov. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
09 nov. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Final Phase 3 results of AXS-05 in treatment resistant depression now anticipated in 1Q 2019 Final Phase 2 results of AXS-05 in major depressive disorder anticipated around year-end 2018 Phase 2/3...